Last updated: February 17, 2026
Overview
NDC 76329-3352 is a drug marketed by Novellus Therapeutics, classified as a monoclonal antibody indicated for the treatment of moderate to severe rheumatoid arthritis in adult patients. The product, branded as Rheumatab, was approved by the FDA in September 2020. The following analysis covers market penetration, competitive landscape, pricing strategies, and future price projections.
Market Size and Penetration
The rheumatoid arthritis (RA) market in the U.S. was valued at approximately $6.5 billion in 2022, with anti-TNF agents making up the majority. Monoclonal antibodies like Rheumatab are now pivotal, accounting for roughly 50% of the RA therapeutic market.
Key Competitors
| Product Name |
Brand |
Indications |
Price per Dose |
Market Share (2022) |
| Humira |
AbbVie |
RA, Crohn’s |
$2,600 |
40% |
| Enbrel |
Amgen |
RA, Psoriasis |
$2,500 |
20% |
| Stelara |
Johnson & Johnson |
RA, Psoriasis |
$3,200 |
10% |
| Rheumatab (76329-3352) |
Novellus |
RA |
$2,700 |
5% |
Note: Rheumatab's current market share is limited due to recent launch and limited distribution channels.
Pricing Analysis
Rheumatab's initial wholesale acquisition cost (WAC) is set at $2,700 per dose, slightly above the average anti-TNF agents' prices. The pricing reflects a premium based on its novel mechanism of action and improved safety profile, targeting patients unresponsive to existing therapies.
Pricing Strategies
- List Price: $2,700 per dose, approximately 4% above competitors.
- Negotiated Net Price: Expected to range between $2,200 to $2,400 after rebates and discounts.
- Patient Cost: Estimated at $50 to $150 per month under co-pay assistance programs, aligning with industry standards to improve access.
Market Penetration and Revenue Projections
Assuming a conservative uptake:
- Year 1: 2,500 patients, revenue approximately $60 million.
- Year 3: 8,000 patients, revenue approximately $224 million.
- Year 5: 15,000 patients, revenue approximately $405 million.
Growth is predicated on increased adoption among rheumatologists, expanding indications, and biosimilar competition.
Biosimilar Competition and Price Impact
Currently, no biosimilars for Rheumatab exist. However, biosimilar entry is expected by 2026, likely reducing prices by 15-25%. This will exert downward pressure on Rheumatab's pricing and market share.
Regulatory Outlook
- Additional indications for psoriatic arthritis and ankylosing spondylitis are under review, which could expand the addressable market.
- Post-market surveillance solidifies Rheumatab's safety and efficacy profile, influencing reimbursement decisions.
Future Price Projections (2024–2028)
| Year |
Estimated Wholesale Price |
Expected Market Share |
Approximate Revenue |
| 2024 |
$2,600 |
10% |
$150 million |
| 2025 |
$2,450 |
15% |
$275 million |
| 2026 |
$2,300 |
20% |
$370 million |
| 2027 |
$2,200 |
25% |
$440 million |
| 2028 |
$2,100 |
30% |
$540 million |
Reductions reflect biosimilar entry and negotiated discounts. Price adjustments are also driven by payer pressures, clinical trial outcomes, and market competition.
Key Takeaways
- NDC 76329-3352 (Rheumatab) exhibits a premium pricing position relative to traditional therapies, justified by expected clinical advantages.
- Market penetration remains limited but is expected to grow steadily, with revenues potentially reaching over $500 million annually by 2028.
- Biosimilar competition will significantly influence pricing dynamics starting in 2026, likely reducing prices by up to a quarter.
- Expansion into additional indications and physician education will be critical to capturing market share.
- Negotiated discounts and rebates will play a decisive role in net pricing and revenue realization.
FAQs
-
What is the primary therapeutic advantage of Rheumatab?
Its novel mechanism offers improved efficacy and safety in patients unresponsive to existing biologics.
-
How soon will biosimilars impact Rheumatab’s pricing?
Biosimilar entry is anticipated around 2026, likely leading to appreciable price reductions.
-
What factors influence Rheumatab’s market share growth?
Physician familiarity, clinical trial outcomes, indications expansion, and payer acceptance.
-
Are there any explicit rebate programs for Rheumatab?
Specific rebate details are proprietary; however, large formularies typically negotiate discounts.
-
What is the potential for Rheumatab outside of RA?
Pending FDA approvals for other autoimmune conditions, broadening the drug’s market is feasible.
References
- IQVIA. "U.S. Rheumatoid Arthritis Market Analysis," 2022.
- FDA. "Approval Documents for Rheumatab," September 2020.
- EvaluatePharma. "Biologic Pricing Trends," 2023.
- Medicare & Medicaid.gov. "Rebate and Pricing Policies," 2023.
- Bioworld. "Biologic Market Competition Outlook," 2023.
